Navigation Links
Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
Date:11/3/2008

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the third quarter and nine months ended Sept. 30, 2008, after the close of market on Nov. 10, 2008. The company's earnings conference call will take place Nov. 10, 2008, at 2 p.m. PST (5 p.m. EST).

Both live events will be available for viewing on Trubion's website at http://investors.trubion.com/events.cfm.

Third-Quarter and Nine Months Earnings Conference Call: 2 p.m. PST/5 p.m. EST, Nov. 10, 2008

Trubion will host a conference call and webcast to discuss its third-quarter and nine months 2008 financial results. The call will be held Nov. 10 at 2 p.m. PST (5 p.m. EST). The live event will be available on Trubion's website at http://investors.trubion.com/events.cfm, or by calling (877) 440-5804 or (719) 325-4881. A replay of the discussion will be available beginning the evening of Nov. 10 on Trubion's website or by calling (888) 203-1112 or (719) 457-0820, and entering 8489656. The telephone replay will be available through Nov. 17, 2008.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com.

TRBN-G

Contact:

Jim DeNike

Senior Director, Corporate Communications

Trubion Pharmaceuticals Inc.

(206) 838-0500

jdenike@trubion.com

http://www.trubion.com

Waggener Edstrom Worldwide Healthcare

Colleen Beauregard

Senior Vice President

(617) 576-5790

colleenb@waggeneredstrom.com


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
2. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
3. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
4. Trubion Announces Presentations at Upcoming Investor Conferences
5. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
6. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
7. Genesis Pharmaceuticals Files Counter Claims
8. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
10. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
11. ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2018)... ... ... The Myers’ have been doing this for five years. This year’s event takes ... 91326. , “The Harvest Festival is another way we like to give back to ... Hospital LA,” said Kris and Keith. , The event includes a 50/50 raffle, where ...
(Date:10/16/2018)... ... October 16, 2018 , ... Bastyr University is pleased ... Integrative Health and Medicine’s (AIHM) Visionary Award for his passionate efforts in forging ... was selected as AIHM’s recipient of the Visionary Award due to his tireless ...
(Date:10/16/2018)... Del. (PRWEB) , ... October 16, 2018 , ... ... of First Healthcare Compliance, an attorney experienced in employment law, writes frequently on ... other publications. Recently, she authored a chapter in the Health Care Compliance Professional's ...
(Date:10/16/2018)... ... October 16, 2018 , ... ... healthcare and clinical research networking-technology company founded by patient-survivors, and The Avoca ... compliance in the clinical trial execution process, today announced its mutual collaboration ...
(Date:10/13/2018)... ... October 13, 2018 , ... This World Food Day – ... it IS possible to end hunger by 2030 by breaking a GUINNESS WORLD RECORDS ... of their 28 U.S. based locations and five international locations together to break the ...
Breaking Medicine News(10 mins):
(Date:10/16/2018)... (PRWEB) , ... October 16, 2018 , ... ... today announced its participation in the American Academy of Ophthalmology’s (AAO) annual session. ... of Ophthalmology October 27-30 at McCormick Place in Chicago. AAO 2018 is a ...
(Date:10/16/2018)... ... October 16, 2018 , ... With suicide as the tenth leading cause ... American Psychiatric Nurses Association (APNA) has released a new training to equip nurses working ... by suicide in hospital settings are preventable, a recent survey of 15,000 health and ...
(Date:10/13/2018)... ... October 12, 2018 , ... David Young ... which was used in the Lockheed F22 Aircraft. Today, he announces the invention ... AF-Arrhythmia, which can lead to sudden cardiac death (SCD). , The Two-Dimensional Arrhythmia ...
Breaking Medicine Technology: